Phase I multi-center clinical and biomarker study of the dual-action androgen receptor inhibitor ONCT-534
{{output}}
ONCT-534 is a dual-action androgen receptor inhibitor (DAARI) that combines AR antagonism and degradation via N-terminal domain binding, additionally targeting AR splice variants. In this study patients received ONCT-534 daily ranging from 40 to 1200 mg. The p... ...
